These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 32554246

  • 21. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
    Ceballos MP, Angel A, Delprato CB, Livore VI, Ferretti AC, Lucci A, Comanzo CG, Alvarez ML, Quiroga AD, Mottino AD, Carrillo MC.
    Eur J Pharmacol; 2021 Feb 05; 892():173736. PubMed ID: 33220273
    [Abstract] [Full Text] [Related]

  • 22. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    Gao L, Morine Y, Yamada S, Saito Y, Ikemoto T, Tokuda K, Takasu C, Miyazaki K, Shimada M.
    PLoS One; 2021 Feb 05; 16(9):e0256755. PubMed ID: 34473785
    [Abstract] [Full Text] [Related]

  • 23. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
    Makol A, Kaur H, Sharma S, Kanthaje S, Kaur R, Chakraborti A.
    Clin Mol Hepatol; 2020 Jan 05; 26(1):45-53. PubMed ID: 31564085
    [Abstract] [Full Text] [Related]

  • 24. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
    Xiao Y, Sun Y, Liu G, Zhao J, Gao Y, Yeh S, Gong L, Chang C.
    Cancer Lett; 2019 Mar 01; 444():175-187. PubMed ID: 30448543
    [Abstract] [Full Text] [Related]

  • 25. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S, Ji L, Tao L, Pan Y, Lin Z, Wan Z, Pan H, Zhao J, Cai L, Xu J, Cai X.
    Cell Mol Gastroenterol Hepatol; 2021 Mar 01; 12(3):1121-1143. PubMed ID: 33962073
    [Abstract] [Full Text] [Related]

  • 26. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
    Sukowati CH, Rosso N, Pascut D, Anfuso B, Torre G, Francalanci P, Crocè LS, Tiribelli C.
    BMC Gastroenterol; 2012 Nov 15; 12():160. PubMed ID: 23153066
    [Abstract] [Full Text] [Related]

  • 27. Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
    Wei CT, Chen LC, Hsiang YP, Hung YJ, Chien PH, Pan HL, Chen YJ.
    Anticancer Res; 2019 Feb 15; 39(2):695-701. PubMed ID: 30711947
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L, Huang X, Chen J, Zhang K, Gu YH, Sun J, Cui SY.
    Mol Cancer Ther; 2020 May 15; 19(5):1197-1209. PubMed ID: 32220970
    [Abstract] [Full Text] [Related]

  • 31. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 15; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 32. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I.
    Mol Oncol; 2019 May 15; 13(5):1311-1331. PubMed ID: 30959553
    [Abstract] [Full Text] [Related]

  • 33. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

  • 34. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 30; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 35. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y, Pan G, Chen L, Ma S, Zeng T, Man Chan TH, Li L, Lian Q, Chow R, Cai X, Li Y, Li Y, Liu M, Li Y, Zhu Y, Wong N, Yuan YF, Pei D, Guan XY.
    Gastroenterology; 2015 Oct 30; 149(4):1068-81.e5. PubMed ID: 26099525
    [Abstract] [Full Text] [Related]

  • 36. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y, Jiang H, Gao H, Kong J, Zhang P, Hu S, Shi B, Zhang P, Yao M, Li Z.
    Neoplasia; 2012 Jun 30; 14(6):509-18. PubMed ID: 22787432
    [Abstract] [Full Text] [Related]

  • 37. Thyroid hormone T3 augments the cytotoxicity of sorafenib in Huh7 hepatocellular carcinoma cells by suppressing AKT expression.
    Uyulgan S, Köse SN, Kıpçak A, Başkan Y, Dağlar G, Karagonlar ZF, Yandım C.
    J Cancer Res Ther; 2024 Apr 01; 20(3):755-762. PubMed ID: 39023579
    [Abstract] [Full Text] [Related]

  • 38. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 01; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 39. MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma.
    Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F.
    Cancer Res; 2020 Apr 15; 80(8):1720-1734. PubMed ID: 32015093
    [Abstract] [Full Text] [Related]

  • 40. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
    Guo XL, Wang HB, Yong JK, Zhong J, Li QH.
    Eur Rev Med Pharmacol Sci; 2018 Oct 15; 22(20):6667-6677. PubMed ID: 30402839
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.